Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Week 37

September 7 – 13, 2026 · 2 articles

Clinical · Molecular biology

The landscape of peripheral blood RNA modifications and its clinical implications for diagnosis of hepatocellular carcinoma

Ge L, Shang M, He X, et al.

Cell communication and signaling

This study investigated the landscape of RNA modifications in the peripheral blood of patients with hepatocellular carcinoma (HCC), liver cirrhosis, and healthy controls. Using liquid chromatography-tandem mass spectrometry, 55 RNA modifications were quantified, revealing 11 significantly altered modifications in HCC patients, including those at stage I. N2,N2-dimethylguanosine (m2,2G) emerged as the most profoundly dysregulated. A diagnostic model based on a panel of modifications including m2,2G, combined with IFI27 and CCR2 gene expression, demonstrated promising diagnostic performance for HCC, especially for early stages, with high AUCs. These findings suggest the potential for novel diagnostic biomarkers for HCC.

Clinical · Molecular biology

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

Elgedawy GA, Adbelmoneum RA, Aldesoky AI, et al.

BMC cancer

This prospective case-control study investigated the potential of circulating cell-free DNA (cfDNA) as a non-invasive biomarker for ovarian cancer. Researchers quantified cfDNA levels in 50 ovarian cancer patients, 50 patients with benign ovarian lesions, and 50 controls. Results revealed significantly higher cfDNA levels in the malignant group. cfDNA demonstrated strong discriminatory capability for predicting ovarian cancer, its late stage, and mortality, with high AUC values. The study concludes that cfDNA could serve as a diagnostic and prognostic biomarker for ovarian cancer, supporting its use in risk stratification and treatment planning.